CClinicalTrials.gg
CompletedNCT05187494Updated Jan 11, 2022

Enhancing the Efficiency of EMLA Cream in Palatal Anesthesia for Children

An interventional study of Conventional local palatine injection and EMLA cream only in Extrusion of Tooth, sponsored by Damascus University. Completed at 1 site in Syrian Arab Republic. Open to participants aged 7 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Damascus University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2021, registered Dec 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
7 Years to 11 Years
Sex
All
01

Study summary

The aim of this study is to Avoid traditional palatal local injections when extracting upper primary teeth through enhancing the efficiency of EMLA cream by using drug delivery systems (permeability enhancer (DMSO), oral patches and micro-needle patches) for palatine injection.

Group 1: Conventional local palatine injection (control group). Group 2: EMLA cream only. Group 3 :chemical permeability enhancer DMSO with EMLA cream. Group 4: Oral patches with EMLA Cream. Group 5: Micro-needle patches dissolved with EMLA Cream.

Read the detailed description

The insertion of the needle and the infusion of the anesthetic solution into the palate often uncomfortable for the children and their acceptance of dental treatment. Therefore, there is a need for studies to find ways to replace the palatine injection in the modern dentistry.

Effectiveness of Compound surfactant drugs (EMLA) have strong activity on the palatine tissues. Therefore, it will be chosen as an alternative to the traditional ones and will be enhanced by one of the drug delivery systems (physical/chemical).

Decreased permeability of the palatine mucosa is a major reason behind using drug delivery systems to reach an effective therapeutic level.

To our knowledge, this research will be the first which will be used a method of drug delivery systems to replace traditional palatal needle.

02

Conditions studied

  • Extrusion of Tooth

Keywords

  • EMLA
  • Micro-needle patches
  • Permeability enhancer
  • Oral patches
03

In context

Lead sponsor

Damascus University is the lead sponsor of 206 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • no previous dental experience.
  • Healthy children.
  • Definitely positive or positive ratings of Frank scale
  • Child did not receive any sedative or pain drugs during the last three.
  • Presence of upper primary teeth, an indication for extraction

Exclusion criteria

Exclusion Criteria:

  • Presence of general diseases or health problems.
  • Uncooperative children
  • Children with congenital or idiopathic Methemoglobin
  • Teeth with severe abscesses
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Other
    Conventional local palatine injection

    Conventional palatal injection with anesthetic (lidocaine 2% with Epinephrine 1:80000, Korea) will be performed and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.

    Other: Conventional local palatine injection

  • Experimental
    EMLA cream only

    The palatine mucosa will be dried with a cotton ball 2\*2 and then 0,2 g of Emla cream will be applied for 3 minutes . During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.

    Drug: EMLA cream only

  • Experimental
    chemical permeability enhancer DMSO with EMLA cream

    The palatine mucosa will be dried with a cotton ball and then EMLA cream will be mixed with a permeability enhancer in the laboratory of pharmaceutical industries at the Faculty of Pharmacy at Damascus University according to the following: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.

    Drug: chemical permeability enhancer DMSO with EMLA cream

  • Experimental
    Oral patches with EMLA Cream

    The palatine mucosa will be dried with a cotton ball and then 0.2 g of EMLA cream 5% will be applied by using an oral patch 14\*14 mm for 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.

    Drug: Oral patches with EMLA Cream

  • Experimental
    Micro-needle patches dissolved with EMLA Cream

    The palatine mucosa will be dried with a cotton ball 2\*2 and then 0.2 g of EMLA cream 5% will be applied by using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes.

    Drug: Micro-needle patches dissolved with EMLA Cream

Interventions

  • OtherConventional local palatine injection

    Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness

  • DrugEMLA cream only

    Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.

  • Drugchemical permeability enhancer DMSO with EMLA cream

    Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.

  • DrugOral patches with EMLA Cream

    EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness

  • DrugMicro-needle patches dissolved with EMLA Cream

    EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.

06

What researchers measure

Primary outcomes

  1. Changes in the values of each of the heart rate and oxygen rate

    The heart and oxygen rate will be recorded by pulse oximeter

    Time frame: On application of the substance

  2. Evaluation conventional local palatine injection

    The heart and oxygen rate will be recorded by pulse oximeter

    Time frame: On palatal probing

  3. Evaluation conventional local palatine injection

    The heart and oxygen rate will be recorded by pulse oximeter

    Time frame: On extraction

  4. Pain levels using self-reported Wong-Baker faces pain scale

    0= "no hurt", 2= "hurts a little bit", 4="hurts a little more", 6= "hurts even more", 8= "hurts a whole lot", 10= "hurts worst"

    Time frame: On application of the substance

  5. Pain levels using self-reported Wong-Baker faces pain scale

    0= "no hurt", 2= "hurts a little bit", 4="hurts a little more", 6= "hurts even more", 8= "hurts a whole lot", 10= "hurts worst"

    Time frame: On palatal probing

  6. Pain levels using self-reported Wong-Baker faces pain scale

    0= "no hurt", 2= "hurts a little bit", 4="hurts a little more", 6= "hurts even more", 8= "hurts a whole lot", 10= "hurts worst"

    Time frame: On extraction

  7. Pain levels using FLACC scale

    0 = Relaxed and comfortable, 1-3 = Mild discomfort, 4-6 =Moderate pain, 7-10 = Severe discomfort/pain

    Time frame: On application of the substance

  8. Pain levels using FLACC scale

    0 = Relaxed and comfortable, 1-3 = Mild discomfort, 4-6 =Moderate pain, 7-10 = Severe discomfort/pain

    Time frame: On palatal probing

  9. Pain levels using FLACC scale

    0 = Relaxed and comfortable, 1-3 = Mild discomfort, 4-6 =Moderate pain, 7-10 = Severe discomfort/pain

    Time frame: On extraction

07

Study locations

1 site
  • Damascus University
    Damascus, Syrian Arab Republic
08

References and documents

Publications

  • Munshi AK, Hegde AM, Latha R. Use of EMLA: is it an injection free alternative? J Clin Pediatr Dent. 2001 Spring;25(3):215-9. doi: 10.17796/jcpd.25.3.hn62713500418728. PubMed 12049081 ↗
  • Davidovich E, Wated A, Shapira J, Ram D. The influence of location of local anesthesia and complexity/duration of restorative treatment on children's behavior during dental treatment. Pediatr Dent. 2013 Jul-Aug;35(4):333-6. PubMed 23930632 ↗
  • Barcohana N, Duperon DF, Yashar M. The relationship of application time to EMLA efficacy. J Dent Child (Chic). 2003 Jan-Apr;70(1):51-4. PubMed 12762609 ↗
  • Franz-Montan M, Ribeiro LNM, Volpato MC, Cereda CMS, Groppo FC, Tofoli GR, de Araujo DR, Santi P, Padula C, de Paula E. Recent advances and perspectives in topical oral anesthesia. Expert Opin Drug Deliv. 2017 May;14(5):673-684. doi: 10.1080/17425247.2016.1227784. Epub 2016 Sep 1. PubMed 27554455 ↗
  • Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011 Jan;3(1):89-100. doi: 10.4103/0975-7406.76478. PubMed 21430958 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05187494
Lead sponsor
Damascus University
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
May 20, 2021
Primary completion
Aug 23, 2021
Completion
Sep 27, 2021
Last update
Jan 11, 2022

Study contacts

Farah M Babakurd, DDS
principal investigator · MSc student in Pedodontics, University of Damascus
Shadi K Azzawi, Phd
study director · Professor of Pedodontics, Department of Pedodontics, University of Damascus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion